Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
TransCode Therapeutics ( (RNAZ) ) has shared an announcement.
TransCode Therapeutics, Inc. has announced that its 2025 annual meeting of stockholders will take place on August 29, 2025, with a record date set for July 11, 2025. The company has informed stockholders of the change in meeting date, which differs by more than 30 days from the previous year’s meeting, and has set a deadline of June 23, 2025, for the submission of stockholder proposals and director nominations to be included in the proxy materials.
The most recent analyst rating on (RNAZ) stock is a Buy with a $2772.00 price target. To see the full list of analyst forecasts on TransCode Therapeutics stock, see the RNAZ Stock Forecast page.
Spark’s Take on RNAZ Stock
According to Spark, TipRanks’ AI Analyst, RNAZ is a Underperform.
TransCode Therapeutics, as an early-stage biotech firm, presents a high-risk investment profile with significant financial challenges. The lack of revenue and increasing losses, coupled with negative equity, highlight financial instability. Technical indicators suggest continued downward pressure on the stock. The absence of a favorable valuation further impacts its attractiveness. Investors should be cautious given the speculative nature and financial health of the company.
To see Spark’s full report on RNAZ stock, click here.
More about TransCode Therapeutics
Average Trading Volume: 327,538
Technical Sentiment Signal: Sell
Current Market Cap: $6.3M
For detailed information about RNAZ stock, go to TipRanks’ Stock Analysis page.